SMAIO

SMAIO EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of SMAIO (ALSMA.PA) as of Nov 5, 2026 is -16.42. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -21.27 — a change of -22.80% (higher).

EV/EBITDA

-16.42

YoY

-22.80%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of SMAIO is 2025 -16.42 . EV/EBITDA (Enterprise Value to EBITDA) of SMAIO was 2024 -21.27 . It decreases by -22.80% higher compared to the previous year.

The SMAIO EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-65.56 EUR
Jan 1, 2019
-24.87 EUR
Jan 1, 2020
-23.74 EUR
Jan 1, 2021
-19.85 EUR
Jan 1, 2022
8.04 EUR
Jan 1, 2023
111.95 EUR
Jan 1, 2024
-21.27 EUR
Jan 1, 2025
-16.42 EUR
The SMAIO EV/EBITDA history
YEAREV/EBITDAYoY
-16.42-22.80%
-21.27-119.00%
111.95+1,292.19%
8.04-140.51%
-19.85-16.38%
-23.74-4.52%
-24.87-62.07%
-65.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SMAIO Stock analysis

What does SMAIO do? S.M.A.I.O SA generates revenue through its comprehensive suite of medical devices and software solutions designed for spinal surgery. The company offers the Kheiron Spinal Fixation System, which includes implants for immobilizing and stabilizing spinal segments during fusion procedures. Its software solutions, such as i-plan, i-perform, i-check, and i-learn, provide spine surgeons with surgical planning, procedure control, outcome data analysis, and educational resources. The firm targets spine surgeons and specialists in spinal pathologies who require advanced tools for vertebral fusion procedures. The company's revenue streams include the sale of implantable devices like the Kheiron Spinal Fixation System and licensing of its software platforms, including Keops and Balance Analyzer 3D. These products are marketed to spine surgery specialists who use the clinical data and imaging tools to enhance surgical outcomes. The firm's offerings integrate software, devices, and services to address spinal pathologies requiring surgical intervention. S.M.A.I.O SA's business model focuses on delivering end-to-end solutions for spine surgery, combining hardware, software, and educational services. The Kheiron Spinal Fixation System serves as a core product for spinal immobilization, while Keops and Balance Analyzer 3D cater to surgical planning and patient data management. These products are sold directly to spine surgeons and medical specialists who rely on the company's integrated approach to improve surgical precision and patient outcomes. SMAIO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SMAIO stock

EV/EBITDA (Enterprise Value to EBITDA) of SMAIO is -16.42 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of SMAIO changed from -21.27 to -16.42, representing a -22.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) SMAIO since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s SMAIO with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SMAIO

All Key Metrics — SMAIO